Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Value Analysis

Moreover, the 36-month beta value for ADAP is 2.40. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 1 as “sell.”

The public float for ADAP is 222.66M and currently, short sellers hold a 1.40% of that float. On April 04, 2024, ADAP’s average trading volume was 1.89M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ADAP) stock’s latest price update

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s stock price has plunge by -1.43relation to previous closing price of 1.40. Nevertheless, the company has seen a -9.21% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-01-16 that Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

ADAP’s Market Performance

Adaptimmune Therapeutics Plc ADR (ADAP) has seen a -9.21% fall in stock performance for the week, with a -6.76% decline in the past month and a 84.99% surge in the past quarter. The volatility ratio for the week is 7.56%, and the volatility levels for the past 30 days are at 11.48% for ADAP. The simple moving average for the last 20 days is -8.61% for ADAP stock, with a simple moving average of 57.27% for the last 200 days.

Analysts’ Opinion of ADAP

Many brokerage firms have already submitted their reports for ADAP stocks, with Bryan Garnier repeating the rating for ADAP by listing it as a “Buy.” The predicted price for ADAP in the upcoming period, according to Bryan Garnier is $3.60 based on the research report published on March 24, 2023 of the previous year 2023.

Guggenheim, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $5. The rating they have provided for ADAP stocks is “Buy” according to the report published on January 03rd, 2023.

Mizuho gave a rating of “Buy” to ADAP, setting the target price at $9 in the report published on November 09th of the previous year.

ADAP Trading at 4.49% from the 50-Day Moving Average

After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.68% of loss for the given period.

Volatility was left at 11.48%, however, over the last 30 days, the volatility rate increased by 7.56%, as shares sank -5.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +90.00% upper at present.

During the last 5 trading sessions, ADAP fell by -9.21%, which changed the moving average for the period of 200-days by +36.63% in comparison to the 20-day moving average, which settled at $1.5060. In addition, Adaptimmune Therapeutics Plc ADR saw 74.02% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADAP starting from Rawcliffe Adrian, who sale 30,080 shares at the price of $0.67 back on Jan 17 ’24. After this action, Rawcliffe Adrian now owns 44,848 shares of Adaptimmune Therapeutics Plc ADR, valued at $20,244 using the latest closing price.

Bertrand William C JR, the Chief Operating Officer of Adaptimmune Therapeutics Plc ADR, sale 18,908 shares at $0.67 during a trade that took place back on Jan 17 ’24, which means that Bertrand William C JR is holding 7,785 shares at $12,725 based on the most recent closing price.

Stock Fundamentals for ADAP

Current profitability levels for the company are sitting at:

  • -2.38 for the present operating margin
  • 0.84 for the gross margin

The net margin for Adaptimmune Therapeutics Plc ADR stands at -1.9. The total capital return value is set at -0.68. Equity return is now at value -187.96, with -37.31 for asset returns.

Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -5.58. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 28711.57.

Currently, EBITDA for the company is -127.91 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of 3.23. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.85.

Conclusion

To wrap up, the performance of Adaptimmune Therapeutics Plc ADR (ADAP) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts